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WE hypothesized that foetal administration of SQ-29,548,
a putative thromboxane receptor blocker, would prevent
foeto-placental vasoconstriction produced by the throm-
boxane mimic U46619. Arterial blood gases, continuous
monitoring of maternal and foetal heart rates and blood
pressures were performed in chronically catheterized preg-
nant ewes. Foetal blood flows and vascular resistance were
determined with radioactive microspheres. SQ-29,548
effectively blocked the expected vasoconstrictive effects of
thromboxane. However, prolonged infusion of SQ-29,548
resulted in significant decreases in umbilical-placental
blood flow and foetal mean arterial pressure. This was
accompanied by a respiratory acidemia. Potential therapy
for the vasoconstrictive disorders of pregnancy with SQ-
29,548 awaits further investigation of its intrinsic vaso-
active properties in the umbilical-placental vasculature.
Key words: Foetal blood flow, Placental blood flow, SQ-
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Introduction
The arachidonic acid metabolite thromboxane
(TX) causes peripheral vasoconstriction in the
foetus and decreased utero-placental blood flow.
These effects are balanced by the vasodilatory
actions of prostacyclin (PGI). The normal term
human placenta produces approximately equal
amounts of TX and PGI. In contrast, in pre-
eclampsia the placental production of TX is
increased three-fold while PGI production is less
than half of normal. This eicosanoid imbalance is
central to current concepts of the pathophysiology
of preeclampsia. This imbalance favours the
vasoconstrictive effects ofTX both peripherally and
in the umbilical-placental circulation,
2 and has been
postulated to account for the clinical manifestations
of the disease. Potential therapy for this disorder
should therefore be directed at correcting the
TX/PGI imbalance. Potential methods to accomp-
lish this include: increasing PGI production,
inhibition of TX synthesis or blockade of the
biological actions of TX. PGI administration has
been evaluated in the maternal and foetal
compartments without foetal benefit. In pre-
eclamptic women, the clinical condition improves,
although foetal distress and foetal demise after
maternal PGI administration have been reported.
Additionally, in vivo laboratory experiments have
demonstrated significant reductions in umbilical-
placental blood flow occur when PGI is admin-
istered to the vasoconstricted ovine foetus. 4,s TX
synthesis in the placenta in vitro can be reduced by
the administration of low-dose aspirin6’7 and clinical
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trials have investigated its effectiveness in pre-
eclampsia. 8’9 Evidence exists that there is an increase
in TX in the foetal compartment in pregnancies
complicated by preeclampsia.’’ As obstetricians
now have direct access to the foetal circulation, and
previous investigations have not focused on
inhibition of TX effects, this remains a potential
foetal therapy. The effects of SQ-29,548 (SQ), a
putative TX receptor blocker, have been evaluated
in the guinea-pig trachea,
12 rat aorta,
12 rabbit vas
deferens,
3 canine coronary artery
14 and swine
pulmonary vasculature.
15 These studies have
demonstrated SQ to be a pharmacological TX
antagonist via blockade of its vasoactive effects. We
hypothesized that TX receptor blockade with SQ
would prevent the foeto-placental vasoconstriction
caused by TX.
Materials and Methods
Nine pregnant western-bred ewes were studied
between 126 and 132 days of gestation. Pre-
operatively, the animals were given sodium
pentothal, 10 mg kg- i.v., and atropine, 0.6 mg,
i.m. This was supplemented by inhalant fluothane
during the surgical procedure. Polyvinyl catheters
were placed into branches of the maternal femoral
artery and vein, and advanced 25 cm to lie in the
abdominal aorta and vena cava distal to the renal
artery and vein, respectively. The maternal
abdomen was opened through a midline incision
and a foetal hindlimb was exteriorized through an
incision in the uterine wall. An incision was made
in the ventral surface of the hindlimb to expose the
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femoral artery and vein. Polyvinyl catheters were
inserted into these vessels and advanced to lie
distal to the renal artery and vein, respectively. The
uterine incision was closed, and a foetal forelimb
was exteriorized through a separate uterine incision.
An incision was made in the dorsal surface and
polyvinyl catheters inserted in the axillary artery
and vein. These catheters were advanced to lie in
the aortic arch and superior vena cava, respectively.
An amniotic fluid catheter was anchored to the
interior aspect of the uterine wall. The foetus was
given 250 mg of chloramphenicol via a foetal vein,
and aqueous penicillin G, 600 000 units was injected
into the amniotic cavity. All catheters were filled
with heparin 1 000 U/ml. Foetal limb and uterine
incisions were closed with 3-0 silk and the
abdominal incision was closed with 0 polyglycolic
acid (Dexon) sutures. The foetal and maternal
catheters were tunneled subcutaneously and secured
in a pouch on the maternal flank. All skin incisions
were closed with surgical staples. The animals were
maintained in accordance with the NIH Guide for
the Care and Use of Laboratory Animals (NIH
Publication No. 80-23, 1978) in the Animal Care
Center of the University of Texas Medical School
at Houston. The experimental protocol was
approved by our institutional Animal Welfare
Committee (AWC-MS-86-046). The animals were
allowed to recover for 5--7 days after the operation,
at which time normal maternal and foetal arterial
blood gas values were observed. Studies were
conducted with ewes standing quietly in metabolic
cages with unlimited access to food and water.
Maternal and foetal mean arterial pressures and
foetal venous pressure and amniotic cavity pressure
were recorded continuously with an R611 Beckman
physiological recorder (Schiller Park, IL) and
Statham P23Db transducers (Spectramed, Oxnard,
CA). The foetal heart rate was determined using a
cardiotachometer triggered from the pulse pressure
wave in the foetal ascending aorta. Maternal and
foetal distal aortic arterial pH, PO2, PCO2, bi-
carbonate (HCO-) and base excess (BE) were
measured with a Corning 158 blood gas analyser
(Medfield, MA). Temperatures of 37C and 39C,
respectively, were utilized to measure maternal and
foetal blood gas parameters. Foetal haemoglobin
concentrations were measured with an OSM-2
hemoximeter (London Company, Cleveland, OH).
Maternal and foetal serum lactates were measured
enzymatically (Sigma Diagnostics, St. Louis, MO).
Foetal regional blood flow was measured by the
radioactive microsphere technique as previously
described.
16 Approximately 106 microspheres,
15 #m in diameter, labelled with Strontium85,
Scandium46, Tin
113 or Cobaltsv (3M Company, St.
Paul, MN and New England Nuclear, DuPont
Diagnostics-Imaging, North Billerica, MA), were
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injected into the foetal vena cava over 15-30 s.
Simultaneously, an integrated arterial reference
sample was withdrawn from both of the foetal
arterial catheters at 2.06 mlmin
-1 for 2 min
beginning coincidentally with the microsphere
injection. The order of isotope administration was
altered with each experiment to avoid sequencing.
Experimental design" SQ-29,548 (E.R. Squibb and
Sons, Princeton, New Jersey) was dissolved in 95%
ethanol (10 mg ml-1), and further diluted with 9
vol of 2 mM Na2CO3. This solution was freshly
prepared the morning of each experiment. Prior to
the microsphere studies, in a separate series of
experiments, the ethanol/Na2CO3 vehicle was
infused for 120 min via the foetal vena cava in six
animals. Equivalent volumes to the subsequent SQ
bolus and infusion were used to evaluate potential
intrinsic vasoactivity of the vehicle. No foetus
received more than 30 ml of infusate during any
individual experiment. Continuous recording of
maternal and foetal arterial pressures and heart rates
was performed. Maternal and foetal distal aortic
arterial blood gases were measured at 15 min
intervals. The animals were then allowed to recover
for a minimum of 24h before blood flow
experimentation. Prior to the blood flow portion of
each experiment, maternal and foetal arterial
pressures and heart rates were continuously
recorded. As the active metabolite of TX (TXA2)
is extremely labile, it is necessary to use the stable
analogue U46619 for experimental studies. After
normal maternal and foetal arterial blood gases were
demonstrated, the TX mimic U46619 (Upjohn,
Kalamazoo, MI) at a concentration of 5/g ml-1 in
sterile 0.9% saline, was infused into the foetal vena
cava at a rate of 5 #g min -1. Maternal and foetal
arterial blood gases and serum lactates were
obtained after 20 min of infusion to document
vasoactivity. This dosage would be expected to
produce foetal hypertension, bradycardia and
significant reductions in arterial pH. The animals
were allowed to recover for at least 2 h before
further experimentation. A return to baseline values
in maternal and foetal arterial blood gases, heart
rates and mean arterial pressures was documented
prior to beginning the blood flow portion of the
experiment. Maternal and foetal arterial pressures
and heart rates were again continuously recorded.
Maternal and foetal haemoglobin concentrations
were obtained after each microsphere injection.
Maternal and foetal arterial blood gases, serum
lactates and foetal blood flows were measured in
the control period. A bolus injection of 1.0 mg of
SQ was given via the foetal vena cava over a 1 min
period. An infusion of SQ at 0.2 mgkg
foetus-
h-
was then begun. Maternal and foetal
arterial blood gases, serum lactates and foetal bloodFoetal responses to thromboxane receptor blockade
flows were assessed 20 min after commencement of
the SQ infusion (SQ). TX mimic (TX) was then
infused into the foetal vena cava at a dose of
5/ig min
-1 while maintaining the SQ infusion. All
measurements were repeated 20 min after adding
the TX to the SQ infusion (SQ + TX). The TX
infusion was then discontinued. The SQ infusion
was continued and all measurements were then
repeated 30min later (SQ + 70). Maternal and
foetal arterial blood gases and serum lactates were
repeated after a further 30 min of SQ infusion
(sq + 00).
Radioactive microsphere analysis" After each experiment
was completed, the animals were killed with an
10 ml i.v. injection of T-61 Euthanasia (Hoechst-
Roussel, Agri-Vet, Sommerville, NJ). The foetal
brain, heart, kidneys, small and large intestine,
hindlimb and upperlimb skeletal muscle and
placental cotyledons were dissected from other
foetal tissues. Appropriate intravascular placement
of all catheters was verified at autopsy. All tissues
were ashed and radioactivity was assayed with a
Nuclear Data convertible multichannel analyser
(Schaumburg, IL) connected to a Tracor sodium
iodide crystal detector and sample changer
(Chicago, IL). Known standards of each isotope
were assayed simultaneously. The number of
microspheres in, and blood flow to, each organ was
calculated by modification of a peak search program
developed by Nuclear Data for our laboratory.
Blood flow to each organ was calculated using the
arterial reference sample appropriate to its anatomi-
cal location. Vascular resistance was defined as
mean arterial pressure minus venous pressure minus
amniotic cavity pressure divided .by blood flow to
an organ, and expressed as mmHgm1-1 min.
Amniotic cavity pressure was subtracted from both
mean arterial and venous pressure prior to
calculation of the vascular resistance. Umbilical
placental blood flow was expressed as
ml min- kg-1 foetal weight of tissue. Brain,
cardiac, renal, intestinal and skeletal muscle blood
flow was expressed as ml min- 100 gm- of tissue.
All organs studied and all arterial reference samples
contained greater than 400 microspheres and
thereby satisfied criteria for accuracy of blood flow
measurements within -+-10% by the radioactive
microsphere technique.
17
Statistical analysis. Statistical analysis was done by
two-way analysis of variance with random block
and paired t-test as appropriate, using computer
statistical software (Abstat, Anderson-Bell, Parker,
Co.). Logarithmic transformation [log(x + 1)] was
used when variances were not equal. A probability
of p < 0.05 was chosen to represent statistical
significance. All data are expressed as mean -t- SE.
Results
Maternal heart rate, mean arterial pressure,
arterial blood gas parameters and blood lactate
levels were not significantly altered at any time
during experimentation. Similarly, no significant
changes in amniotic cavity or foetal venous pressure
were observed during any study period. There were
no alterations in maternal arterial blood gas
parameters, or foetal haemoglobin concentrations
at any time during experimentation.
Vehicle infusion" No significant changes in foetal or
maternal cardiorespiratory parameters were ob-
served during infusion of the ethanol/NaeCO3
vehicle over the 120 min infusion period. The
prolonged vehicle infusion time was chosen due to
its technical ease, and to ensure that the
ethanol/Na2CO3 vehicle exhibited no cumulative
intrinsic vasoactivity with extended administration.
Foetal heart rate varied from 164 q- 4 beats per min
(bpm) at the control time period, to 167 -t- 5 bpm
at 120 min (range" 157 -+- 8 to 174 -+_ 9 bpm). Foetal
mean arterial pressure went from 39.4 + 2.2 at
control, to 40.6 + 2.5 mmHg at 120 min (range"
37.9 _-+ 3.7 to 42.5 -+- 1.7). Control arterial pH was
7.40 __+ 0.02, with 7.39 _--k 0.01 observed after 120
min (range" 7.38-+-0.02 to 7.41_ 0.02). There
were no statistically significant differences in the
above measurements during the 120 min evaluation
period (p > 0.20). Similarly, there were no
statistically significant changes in foetal arterial pOe,
pCO2,HCO- and BE throughout the vehicle infusion
(p > 0.20).
U46619 effects. Foetal bradycardia and hypertension
were demonstrated in response to the test dose of
i.v. U46619 at 5/lg min-. Foetal heart rate fell
from 167 _--+- 4 to 131 -+- 13 bpm (p < 0.05) (Fig. 1),
and mean arterial pressure rose from 38.7 1.4 to
48.6 _q- 2.0 mmHg (p < 0.05) (Fig. 1). Foetal heart
rate was not significantly altered from control
values at any other time during the study. The test
dose of TX mimic U46619 caused a significant
deterioration in foetal acid-base status. This was
demonstrated by significant reductions in pH,
pO2 and BE, from 7.39 +/-0.02 to 7.33_+0.03,
26.7 q-2.1 to 22.8 _-+- 2.6 torr, and 2.5 _-+ 1.8 to
-1.9 + 2.6, respectively @ < 0.05). This was
accompanied by significant elevations in pCO2 from
42.8 __+ 2.1 to 48.3 q- 1.5 torr (p < 0.05). Bicarbo-
nate was not significantly altered by the test infusion
of TX mimic. Analysis of foetal blood lactates
revealed a significant increase after administration
of U46619 from 31.2 -+- 3.6 to 38.3 __+ 2.9 mg d1-1
(p < 0.05) (Fig. 2).
SQ-29,548 infusion: No significant alterations in foetal
heart rate or arterial pressures were noted after 20
min of SQ infusion. However, a significant decrease
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FIG. 1. Foetal heart rate in the left panel, and foetal mean arterial pressure in the right panel. PRE" baseline time period; TX" textT mimic time period’
CON" control time period" SQ: 20 min of SQ infusion; SQ + TX" simultaneous SQ and TX mimic infusion’ SQ + 70" 70 min of SQ infusion" SQ + 100:
100 min in total of SQ infusion. All data are mean -I- SE, n 9. *p < 0.05 vs. PRE; **p < 0.05 vs. CON.
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FIG. 2. Foetal blood lactates. PRE: baseline time period" TX: test TX mimic
time period’ CON" control time period’ SQ" 20 min of SQ infusion"
SQ + TX: simultaneous SQ and TX mimic infusion" SQ + 70:70 min of
SQ infusion" SQ + 100" 100 min in total of SQ infusion. All data are
mean ___
SE, n 8. *p < 0.05 vs. control (CON).
in foetal mean arterial pressure from 40.0 __+ 1.4 at
control time period (CON) to 33.5 4.5 mmHg
was present after 100 min of SQ infusion
(SQ + 100) (Fig. 1). During the blood flow portion
of the experiment, foetal arterial blood gases were
not significantly altered from control values after
20 min of SQ infusion (SQ) (Table 1). However,
after 70 and 100 min of SQ administration,
significant decreases in foetal pH and pO2 were
observed, from 7.41 q- 0.02 to 7.36 q-_ 0.01 and
26.5 3.0 to 21.7 -+- 2.3 tort, respectively. Foetal
pCO2 was significantly elevated after 100 min of SQ
infusion from 45.9 + 2.0 to 48.9 + 2.0 torr. There
were no changes in foetal HCO or BE during the
microsphere studies (Table 1). Umbilical-placental
blood flow was not altered from control levels
(CON) after 20 min of sq infusion (sq) (Fig. 3).
Unexpectedly, umbilical-placental blood flow was
significantly reduced from the control value of
292.3 + 32.4 to 205.1 q- 22.3 ml min
-1 kg
-1 foetal
weight after 70 min of SQ infusion (SQ + 70)
(p < 0.05). This reduction in umbilical-placental
blood flow was significantly different from the
control and SQ values, and was temporally related
to the changes in foetal acid-base status. Similarly,
umbilical-placental vascular resistance was not
altered after 20 min of SQ infusion (Fig. 4).
However, umbilical-placental vascular resistance
was significantly increased after 70 min of SQ
infusion from 0.15 + 0.02 to 0.20 + 0.02
mmHgml-
minkg foetal weight. Blood flow
and resistance to specific foetal organ vascular beds
was evaluated. Blood flow to the brain, heart,
kidney, intestine and skeletal muscle was not
Table 1. Foetal arterial blood gases
pH PO2(torr) PCO2(torr) HCO (meq/I) BE
CON 7.41 +_ 0.02 26.5 _+ 3.0 45.9 _+ 2.0 27.4 _+ 1.3 3.1 _+ 1.2
SQ 7.40 _+ 0.02 26.7 _+ 3.1 42.9 +_ 2.9 26.2 _+ 1.8 2.4 _+ 1.6
SQ + TX 7.38 + 0.01 25.3 + 3.6 44.1 + 2.4 25.5 + 1.8 1.3 + 1.7
SQ + 70 7.37 _+ 0.01 22.4 _+ 1.9* 46.5 _+ 2.3 26.4 ___
1.5 2.2 _+ 1.5
SQ + 100 7.36 _+ 0.01 21.7 _+ 2.3* 48.9 _+ 2.0* 25.9 + 1.5 2.7 + 1.7
CON" control time period; SQ: 20 min of SQ infusion" SQ + TX" simultaneous SQ and TX mimic infusion"
SQ + 70" 70 min of SQ infusion" SQ + 100" 100 min in total of SQ infusion. All data are mean _+ SE"
n 8" p < 0.05 vs. control.
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FIG. 3. Foetal placental blood flow responses in ml min -1 kg-1 foetal
weight. CON" control time period; sQ: 20 min of SQ infusion; SQ + TX:
simultaneous SQ and TX mimic infusion" SQ + 70:70 min of SQ infusion.
All data are mean SE, n 8. *p < 0.05 vs. CON.
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FIG. 4. Foetal placental vascular resistance responses in mmHg
ml-
min kg-
foetal weight. CON" control time period" SQ" 20 min of
SQ infusion’ SQ +TX" simultaneous SQ and TX mimic infusion"
SQ + 70:70 min of SQ infusion. All data are mean 4- SE, n 8. *p < 0.05
vs. CON.
significantly altered at any of the time periods
analysed (Table 2). Foetal blood lactate pro-
gressively increased throughout the experimental
time period, with significant elevations from
control values after 70 and 100min of SQ
administration (33.1 3.7, 45.5 -+- 5.5 and 50.7 q-
6.3 mg d1-1, respectively) (p < 0.05) (Fig. 2).
sQ-29,548/u46619 simultaneous infusion: The previously
demonstrated foetal hypertension and bradycardia
caused by TX were blocked by SQ (Fig. 1).
Additionally, the alterations in foetal acid-base
status caused by the TX mimic were absent (Table
1). The expected decrease in umbilical-placental
blood flow during TX administration (SQ + TX)
was eectively blocked (Fig. 3). The expected
increase in placental vascular resistance with TX
administration did not occur (Fig. 4). Indeed, the
reported decrease in blood flow to the renal,
gastrointestinal and skeletal muscle vascular beds
which has been previously reported with this
dosage of TX was not observed (Table 2) (Parisi
VM, Walsh SW, Stockmar ’EJ. Foetal placental
vascular responses to prostacyclin after thrombox-
Table 2. Foetal organ blood flows
CON SQ SQ + TX SQ + 70
Brain 129.0 _+ 16.9 140.3 _+ 17.0 134.1 _+ 16.1 137.8 _+ 21.3
Kidney 199.1 _+ 10.3 190.9 _+ 7.6 188.4 _+ 14.8 176.4 _
14.3
Skeletal muscle 20.0 + 4.2 16.8 _+ 2.0 14.3 _+ 2.3 16.4 _+ 2.6
Intestine 67.2 +_ 9.0 76.1 +_ 13.1 66.9 _+ 7.9 67.6 -+ 9.9
Heart 218.8 _+ 16.2 235.5 _+ 13.9 214.4 + 30.8 217.5 _+ 27.4
CON" control time period; SQ" 20 min of SQ infusion" SQ + TX’ simultaneous SQ and
TX mimic infusion" SQ + 70" 70min of SQ infusion. All data are mean _+ SE"
n 8; all vaues not significantly different from control.
Table 3. Calculated foetal organ vascular resistance
CON SQ SQ + TX SQ + 70
Brain 0.34 _+ 0.05 0.30 -I- 0.03 0.33 _+ 0.06 0.32 _+ 0.05
Kidney 0.21 _+ 0.01 0.21 _+ 0.02 0.22 _+ 0.03 0.23 _+ 0.02
Skeletal muscle 2.82 -+ 0.53 2.68 + 0.42 3.28 -+ 0.53 3.24 -+ 0.58
Intestine 0.70 _+ 0.11 0.61 -+ 0.08 0.64 _+ 0.07 0.64 _+ 0.09
Heart 0.19 -I- 0.02 0.16 + 0.01 0.19 _+ 0.03 0.19 _+ 0.03
CON" control time period" SQ" 20 min of SQ infusion; SQ + TX: simultaneous SQ and
TX mimic infusion" SQ+70" 70min of SQ infusion. All data are mean_+SE;
n 8’ all vaues not significantly different from control.
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ane and angiotensin II induced vasoconstriction.
Presented at the 34th annual meeting of the Society
of Gynecologic Investigation, Atlanta, Georgia,
March 18-21, 1987, Abstract @360). Similarly, the
expected increase in vascular resistance to the
kidneys, intestine and skeletal muscle was not
present with simultaneous SQ and TX administra-
tion (Table 3).
Discussion
The finding of an imbalance in TX/PGI
production by the human placenta in preeclampsia
has stimulated discussion regarding potential
therapy for this disease. Previous human research
had focused on correcting the deficiency in PGI by
increasing PGI.
3 Subsequent investigators have
evaluated inhibition of thromboxane production
both in vivo8’9 and in vitro. 6"7 The foetus may be
adversely affected by the increase in thromboxane
production found in pregnancies complicated by
preeclampsia. Since thromboxane is a potent
vasoconstrictor in the ovine foetus,5’18 we invest-
igated modulation of thromboxane vasoactivity as
a potential in utero foetal therapy. Short term foetal
administration of SQ over 20 min did not result in
any significant alterations in foetal heart rate, mean
arterial pressure or arterial blood gas parameters.
No changes in blood flow or vascular resistance
were demonstrated in the umbilical-placental
vasculature. The vascular circulations of the brain,
heart, kidneys, intestine and skeletal muscle were
also not afl:ected by 20 min of SQ infusion. Thus,
foetal administration of SQ over 20 min does not
exhibit intrinsic vasoactivity. Subsequently, how-
ever, a significant decrease in foetal mean arterial
pressure was present at SQ + 100. This change may
represent blockade of endogenous foetal TX,
resulting in a decrease in intrinsic vascular tone.
These alterations may be due to a specific effect of
SQ, or may occur with any thromboxane
antagonist.
The vasoactivity of the thromboxane mimic
U46619 was demonstrated in our study by
significant alterations in foetal cardiorespiratory
parameters. These effects on foetal heart rate, mean
arterial pressure and arterial blood gas parameters
were prevented by foetal administration of SQ. This
was evidenced by the lack of any significant changes
in cardiorespiratory measurements when these
compounds were simultaneously infused. Similarly,
the vasoconstriction in the umbilical-placental
circulation previously demonstrated with foetal
thromboxane administration, was blocked by SQ.
There were no significant alterations in blood flow
or vascular resistance in any of the foetal organs
examined when U46619 and SQ were administered
simultaneously. Indeed, the expected thromboxane-
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induced vasoconstriction in the renal, gastro-
intestinal and skeletal muscle vasculatureTM was
prevented by SQ. These data would appear to
support the actions of SQ as a thromboxane
receptor blocker.
Previous investigations have reported that the
vasoactive effects of U46619 resolve within 30 min
after cessation of foetal infusion (Parisi VM,
Stockmar EJ. Foetal cardiorespiratory responses to
prostacyclin and thromboxane. Presented at the 7th
annual meeting of the Society for Perinatal
Obstetricians, Orlando, Florida, February 2-5,
1987, Abstract = 109). Thus, the umbilical-
placental vasoconstriction observed 30 min after the
discontinuation of the TX mimic infusion (i.e. after
a total of 70 min of SQ infusion) was an unexpected
finding. This umbilical-placental vasoconstriction
was not accompanied by alterations in blood flow
or vascular resistance in the other foetal organs
examined. The respiratory alterations in arterial
blood gas parameters which we observed after 70
and 100 min of SQ infusion, are consistent with this
decrease in umbilical-placental perfusion. The
progressive rise in foetal blood lactate is also
consistent with the observed decrease in umbilical-
placental perfusion. The 25% decrease in skeletal
muscle blood flow may be the origin of this
metabolic product. The lack of statistical signifi-
cance (p -0.11) may be due to the relatively small
number of animals. Additionally, decreased pla-
cental clearance of lactate due to the vasoconstric-
tion in the umbilical-placental circulation may
account for the significant increases in foetal blood
lactate levels during the experimental period.
Our finding of umbilical-placental vasoconstric-
tion after 70 min of SQ infusion is in conflict with
its putative action as a thromboxane receptor
blocker.
2 We speculate that SQ may possess
activity as a weak thromboxane agonist in the
umbilical-placental circulation. This is consistent
with our findings of the absence of short term
vasoactivity, effective thromboxane blockade, and
subsequent vasoconstriction. In this situation, the
lack of changes in perfusion to other organs in the
face of decreased umbilical-placental blood flow
may be due to small reductions in flow throughout
all foetal tissues or to decreases in perfusion to
specific organs which were not examined. De-
creased metabolic clearance of SQ would result in
umbilical-placental vasoconstriction if it is indeed
a weak thromboxane agonist. The speculation that
SQ acts as a weak thromboxane agonist does not
explain the significant decrease in. foetal mean
arterial pressure at SQ + 100. The formation and
action of a vasoactive metabolite of SQ could
represent an alternative explanation for the
temporal delay in umbilical-placental vasoconstric-
tion.Foetal responses to thromboxane receptor blockade
Another speculation which may account for the
observed alteration in foeto-placental blood flow is
passive vasoconstriction of the umbilical-placental
circulation based on Poiseuille’s law. Poiseuille’s
law states that vascular resistance is equal to the
pressure drop across a vascular bed (arter-
ial venous pressure) divided by the rate of blood
flow to an organ. This pressure dierential is usually
estimated by foetal mean aortic blood pressure.
Blood flow to an organ is related to the length and
radius of the afferent vessel and the viscosity of
blood. Since the placenta is the organ furthest from
the heart, blood flow to the placenta must overcome
the greater resistance created by this increased
distance.
19 We speculate that SQ may cause passive
vasoconstriction as well as thromboxane receptor
blockade. In this setting, blood flow would take the
path of least resistance and be preferentially
diverted to organs more proximal to the heart than
the placenta. Since the lung is the most proximal
organ to the heart, and other investigators have
demonstrated pulmonary responsiveness to SQ,
15
this organ may be the recipient of increased blood
flow. According to Poiseuille’s law, an increase in
arterial pressure accompanied by a decrease in blood
flow represents active vasoconstriction. In contrast,
the significant reduction in umbilical-placental
perfusion which we observed represents passive
rather than active vasoconstriction, since foetal
mean arterial pressure and umbilical-placental
blood flow both decreased. The foetal mean arterial
pressure at SQ -+- 70 was decreased, although these
changes did not achieve statistical significance until
100 min of SQ infusion. It is likely that the lack of
significance at SQ + 70 is due to the relatively small
number of animals in our study. Based on the
arterial blood gas findings, it is reasonable to
assume that umbilical-placental blood flow did not
improve at SQ + 100. Thus, based on Poiseuille’s
law, SQ may possess intrinsic vasoactivity which
results in passive vasoconstriction of the umbilical-
placental vasculature.
We conclude that SQ blocks the foetal vascular
response to thromboxane mimic. However, pro-
longed infusion of SQ results in a progressive
deterioration in the foetal acid-base status and
significant reductions in umbilical-placental blood
flow. The physiological mechanism responsible for
these findings remains unclear, and may apply to
other thromboxane antagonists. The clinical re-
levance of these data lies in the potential for therapy
of the vasoconstrictive disorders of pregnancy
associated with an imbalance in the production of
TX/PGI.
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